secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2026-05-14T20:04:23+00:00
Accession:  0002007919-26-000028
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx Q1 2026 net loss $33.4M; cash $161.7M; ozekibart BLA submitted
----------------------------------------------------------------------

- Net loss $33.4M ($2.15/sh) vs $43.3M ($2.80/sh) YoY; R&D expense $25.2M down from $36.9M.
- Cash $161.7M at Mar 31, 2026 vs $124.2M at Dec 31, 2025; $75M loan amendment from Oxford.
- BLA submitted to FDA for ozekibart in conventional chondrosarcoma; discuss accelerated pathways for CRC and Ewing sarcoma.
- INBRX-106 Phase 2 HNSCC updated interim data in May 2026; PFS results expected Q4 2026.
- Debt increased to $175M; other expense $2.5M from higher interest on new $75M principal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/0002007919-26-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/inhibrx-20260514.htm
  HTML page:      https://secwatch.observer/filing/0002007919-26-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer